40
Participants
Start Date
January 31, 2013
Primary Completion Date
March 31, 2019
Study Completion Date
July 3, 2019
Bendamustine
"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:~* CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle~* CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle~Available to qualifying subjects is the option to dose escalate to dose level (+)1:~* 120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)~* 100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
Dexamethasone
40 mg orally on days 1, 8, 15, 22 of each cycle
Mt. Sinai Medical Center, New York
Columbia University, New York
Memorial Sloan-Kettering Cancer Center, New York
Barbara Ann Karmanos Cancer Institute, Detroit
Tufts Medical Center, Boston
Boston Medical Center, Boston
Collaborators (1)
Cephalon
INDUSTRY
Columbia University
OTHER